James CS Chim, MD, PhD

SH Ho Professor in Haematology & Oncology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China

Professor Chim has been awarded Fellowships of both the Royal Colleges of Physicians and Pathologists in the United Kingdom. He has also been awarded Founding Fellowship at the Faculty of Science of the Royal College of Pathologists of Australia & the Academy of Translational Medicine of the European Society for Translational Medicine (EUSTM). 

Prof. Chim is a clinician scientist interested in the study of DNA methylation of tumour suppressor genes and non-coding RNAs (micro-RNAs & long noncoding RNAs) in blood cancers including multiple myeloma, lymphoma and chronic lymphocytic leukemia. He is also an invited member of Clinical Epigenetics Society (CLEPSO) and Cancer Epigenetics Society (CES). 

Internationally, Prof. Chim is a member of the International Myeloma Working Group (IMWG), Executive Council Member of Asian Myeloma Network (AMN), and the Chairman of the Education Program of the Asia Pacific Hematology Consortium (APHCON). Locally, he is the Founding & current Chairman of the Hong Kong Society of Myeloma. Moreover, Prof. Chim has been invited reviewer for American Society of Hematology (ASH) and external reviewer for grant funding organizations including Leukaemia & Lymphoma Research, Leukemia Research (United Kingdom), Cancer Research (United Kingdom), The Agency for Science, Technology and Research (A*Star) of Singapore, & Association for International Cancer Research (AICR), U.S.-Israel Binational Science Foundation (BSF), the Icelandic Research Fund (IRF) & Czech Science Foundation.

As of Dec 2016, Prof. Chim has authored >230 publications in international peer reviewed journals. He is also the Associate Editor of Epigenomics, Clinical Epigenetics, Frontiers in Oncology, & Hematology, & editorial board members of Blood Cancer Journal, Bone Marrow Transplantation, Journal of Hematology & Oncology & Journal of Translational Medicine.